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Comparison of Clinical and Imaging Characteristics and 
Outcomes between Provoked and Unprovoked Acute Pulmonary 
Embolism in Koreans
This study was performed to compare clinical and imaging parameters and prognosis of 
unprovoked pulmonary embolism (PE), provoked PE with reversible risk factors (provoked-
rRF), and provoked PE with irreversible risk factors (provoked-iRF) in Koreans. Three 
hundred consecutive patients (mean age, 63.6 ± 15.0 yr; 42.8% male) diagnosed with 
acute PE were included. The patients were classified into 3 groups; unprovoked PE, 
provoked-rRF, and provoked-iRF; 43.7%, 14.7%, and 41.7%, respectively. We followed 
up the patients for 25.4 ± 33.7 months. Composite endpoint was all-cause mortality and 
recurrent PE. The provoked-iRF group had significantly higher all-cause mortality, 
mortality from PE and recurrent PE than the unprovoked and provoked-rRF groups 
(P < 0.001, P < 0.001, and P = 0.034, respectively). Prognostic factors of composite 
endpoint in the unprovoked group were high creatinine ( > 1.2 mg/dL; P < 0.001; hazard 
ratio [HR], 4.735; 95% confidence interval [CI], 1.845-12.152), C-reactive protein (CRP; 
> 5 mg/L; P = 0.002; HR, 5.308; 95% CI, 1.824-15.447) and computed tomography (CT) 
obstruction index (P = 0.034; HR, 1.090; 95% CI, 1.006-1.181). In conclusion, provoked-
iRF has a poorer prognosis than unprovoked PE and provoked-rRF. Renal insufficiency, 
high CRP, and CT obstruction index are poor prognostic factors in unprovoked PE.
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Cardiovascular Disorders
INTRODUCTION
Acute pulmonary embolism (PE) is a serious, potentially fatal 
disease in Asians as well as Caucasians, although there are ra-
cial differences in the prevalence of PE (1-3). The most common 
source of embolism is deep vein thrombosis of the lower extrem-
ities and pelvis. Virchow’s triad of hemostasis, blood vessel wall 
alterations, and abnormal blood constituents predisposes to 
thrombus formation (4). Classic risk factors for PE or deep vein 
thrombosis are cancer, immobilization, pregnancy, obesity, and 
estrogen supplementation (5). However, some patients with PE 
have no identifiable risk factors. PE associated with classic risk 
factors is categorized as provoked or secondary PE, while PE 
not associated with classic risk factors is categorized as unpro-
voked or spontaneous PE. It has been suggested that PE, partic-
ularly unprovoked PE and atherosclerosis may share common 
risk factors including hypertension, diabetes, smoking, and hy-
percholesterolemia (6-9). However, the clinical and prognostic 
differences between unprovoked PE, provoked PE with revers-
ible risk factors and provoked PE with irreversible risk factors 
have not been definitely determined. In this study we compared 
the clinical and imaging characteristics and prognosis of un-
provoked PE, provoked PE with reversible risk factors, and pro-
voked PE with irreversible risk factors in Koreans.
MATERIALS AND METHODS
Patients
Patients hospitalized with acute PE at a single center in Korea 
from 1998 to 2008 were consecutively included. Patients with 
acute PE confirmed by chest computed tomography (CT), or 
lung perfusion/ventilation scans were included. The diagnostic 
criteria were direct visualization of thrombi in the lumen of the 
pulmonary arteries on enhanced chest CT, or high probability 
on lung perfusion/ventilation scans. Patients with chronic or 
recurrent PE, in addition to patients diagnosed by methods oth-
er than chest CT or lung perfusion/ventilation scans were ex-
cluded. Patients with PE were classified into 3 groups: unpro-
voked, provoked with reversible risk factors (provoked-rRF), and 
provoked with irreversible risk factors (provoked-iRF). Unpro-
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voked PE was defined as PE not related to risk factors including 
cancer, immobilization (due to neurologic sequelae, fracture of 
the lower extremities, major surgery, or admission to ICU due 
to medical disease) for more than a week, pregnancy, or estro-
gen supplement within the past 3 months. Provoked PE was 
defined as PE related to risk factors. Reversible risk factors were 
defined as a recoverable immobilization state, pregnancy, es-
trogen supplementation, and surgically or medically curable 
cancer. Irreversible risk factors were defined as cancer other 
than curable state, and an irrecoverable immobilization state. 
Data collection and parameters 
We reviewed patients’ medical records for clinical parameters, 
imaging findings, and interviewed patients in the outpatient 
clinic or by phone. Clinical parameters included age, sex, body 
mass index (BMI), hypertension, diabetes, current smoking, his-
tory of significant coronary artery disease (CAD) or cerebrovas-
cular accident (CVA), creatinine, total cholesterol, low-density 
lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) 
cholesterol, triglyceride, C-reactive protein (CRP) on the first 
hospital day, B-type natriuretic peptide (BNP) on the first hos-
pital day, D-dimer on the first hospital day, and blood pressure 
(BP) on admission. Shock was defined as systolic BP < 90 mmHg 
or signs of poor tissue perfusion. Imaging data included CT and 
echocardiographic parameters. The dimensions of the right (RV) 
and left (LV) ventricles at the atrioventricular valvular plane and 
diameters of the aorta (Ao) and main pulmonary artery (PA) in 
the axial plane were measured on CT (Fig. 1A, B). RV dimen-
sion/LV dimension (CT RV/LV ratio) and PA diameter/Ao diam-
eter (CT PA/Ao ratio) were calculated. To define CT obstruction 
index, arterial trees of each lung were regarded as 10 segmental 
arteries. The presence of embolism in a segmental artery was 
scored as 1 or 2 points according the degree of obstruction (Fig. 
1C). CT obstruction index (%) was calculated according to the 
equation: ∑ (n × d)/40 × 100, where n = the number of segmen-
tal arteries affected with embolism (1 to 20) and d = degree of 
obstruction (no = 0, partial = 1, and total = 2) (10, 11). If emboli 
were present in the proximal pulmonary artery, the score was 
equal to the number of segmental arteries arising distally. This 
index expresses the percentage of pulmonary arterial obstruc-
tion by thromboemboli. 
 Measurement using 2-dimensional Doppler echocardiogra-
phy was performed according to the guidelines of the American 
Society of Echocardiography (12, 13). LV ejection fraction (LVEF) 
was measured by modified biplane Simpson’s method from 
apical 4-chamber and 2-chamber views. RV end-diastolic di-
mension (RVEDD) was measured at the mid-RV level in apical 
4-chamber view. Severity of tricuspid regurgitations (TR) were 
defined as mild, moderate, and severe according to color TR jet 
area of < 5 cm2, 5 to 10 cm2, and > 10 cm2 in apical 4-chamber 
views, respectively (14). Significant TR was defined as moderate 
to severe TR. Maximal velocity of TR flow was measured by con-
tinuous wave Doppler in the apical 4-chamber view. Systolic 
pulmonary artery pressure (SPAP) was calculated using the con-
ventional simplified Bernoulli equation. Composite endpoint 
was defined as all-cause mortality and recurrence of PE. 
 Clinical factors including age (> 65 yr), sex, BMI (> 25 kg/m2), 
hypertension, diabetes, current smoking, history of significant 
CAD or CVA, creatinine (> 1.2 mg/dL), total cholesterol (> 200 
mg/dL), LDL cholesterol (> 120 mg/dL), HDL cholesterol (< 40 
mg/dL in men, < 50 mg/dL in women), triglyceride (> 150 mg/
dL) (15), CRP (> 5 mg/L), BNP (> 100 pg/mL), D-dimer (> 20 
μg/mL), cancer, metastatic cancer, and shock on admission 
were analyzed as prognostic factors of the composite endpoint. 
As for imaging parameters, CT RV/LV ratio, CT PA/Ao ratio, CT 
obstruction index, RVEDD, significant TR, SPAP, and LVEF were 
analyzed as prognostic factors of composite endpoint. 
Treatment 
Patients were treated by surgery, thrombolytics, unfractionated 
heparin, or low molecular weight heparin according to vital 
signs and at the attending physicians’ discretion. The patients 
in shock on admission were treated by surgery or thrombolyt-
ics. At discharge, warfarin was maintained for all patients with-
out contraindications. Contraindications of warfarin were bleed-
ing diathesis, recent major bleeding, pregnancy, and hypersen-
A CB
Fig. 1. Measurement of CT parameters. Measurement of diameters of the aorta and main pulmonary artery (A), and dimensions of the right and left ventricles (B). (C) An exam-
ple of CT obstruction index; the right (solid arrow) and left (dashed arrow) pulmonary arteries are obstructed totally and partially, respectively. CT obstruction index is 75%. 
Uhm J-S, et al. • Provoked and Unprovoked Pulmonary Embolism
http://jkms.org  1349http://dx.doi.org/10.3346/jkms.2012.27.11.1347
sitivity. Warfarin was maintained with a target prothrombin time 
(international normalized ratio, INR) between 2.0 and 3.0 for, at 
least, 3 to 6 months. If patients had contraindications to antico-
agulation or recurrent PE during maintenance of warfarin, infe-
rior vena cava filtering was performed. 
Follow-up
The patients were followed up at the outpatient clinic on a regu-
lar basis. If patients had acute symptoms including dyspnea 
and chest pain, patients were encouraged to visit the emergen-
cy room. Chest CT or echocardiography was performed accord-
ing to the patients’ complaints. If patients did not visit the out-
patient clinic, we interviewed them by phone.
Statistical analysis 
Results are expressed as the mean ± standard deviation for data 
distributed normally. Baseline characteristics and imaging pa-
rameters were analyzed by ANOVA and chi-squared test. Ka-
plan-Meier method was used for comparison of all-cause mor-
tality, mortality from PE and recurrence rate of PE between the 
groups. Prognostic factors of the composite endpoint were also 
analyzed by univariate and multivariate Cox proportional haz-
ard models. The assumption was assessed by log-minus-log-
survival function and found that the proportion hazards assump-
tion was reasonable. Parameters of a P  value ≤ 0.1 by univari-
ate analysis were included for multivariate analysis. Hazard ra-
tios (HR) and 95% confidence intervals (CI) were calculated. A 
P  value < 0.05 was considered significant. The data were ana-
lyzed using the Statistical Package for the Social Sciences (SPSS, 
version 15.0; SPSS, Inc., Chicago, IL, USA).
Ethics statement
The study protocol was approved by the institutional review 
board of the Seoul St. Mary’ Hospital (IRB No. XC10OIMI0120K). 
Informed consent was exempted by the board because this was 
a retrospective study.
RESULTS
Baseline patient characteristics 
Table 1 reports baseline patient characteristics. Three hundred 
patients (mean age, 63.6 ± 15.0 yr; 42.8% male) were included. 
One hundred thirty-one (43.7%), 44 (14.7%), and 125 (41.7%) 
patients were in the unprovoked, provoked-rRF, and provoked-
iRF groups, respectively. In the provoked group, risk factors in 
order of frequency were cancer, immobilization, and estrogen 
supplementation (Table 2). Lung cancer was the most frequent 
cancer related to PE. Neurologic sequelae were the most fre-
quent causes of immobilization related to PE. The number of 
the patients with metastatic cancer was 65 (58.6% of patients with 
cancer in the provoked group). Mean follow-up period was 25.4 ±  
33.7 months. Twenty-three patients were lost to follow-up.
Clinical factors 
The unprovoked group had significantly more current smokers 
(P = 0.012) and history of CAD (P < 0.001), and less frequent 
history of CVA (P < 0.001) than the provoked groups (Table 1). 
There were no significant differences in age, sex, BMI, hyperten-
sion, diabetes, creatinine, cholesterol, triglyceride, CRP, BNP, 
D-dimer, and frequency of shock on admission between the 3 
groups. 
Table 1. Baseline patients’ characteristics
Parameters Unprovoked (n = 131) Provoked- rRF (n = 44) Provoked-iRF (n = 125) P  value
Age (yr)   61.8 ± 16.5   64.5 ± 16.9   65.1 ± 12.4 0.100
Male sex 63 (48.1%) 15 (34.1%)   50 (40.0%) 0.071
BMI (kg/m2) 23.8 ± 3.7 24.6 ± 4.3 23.0 ± 3.5 0.301
Current smoker 28 (21.4%)*    5 (11.4%)†    13 (10.4%)† 0.012
Hypertension 51 (38.9%) 17 (38.6%)   38 (30.4%) 0.289
Diabetes 25 (19.1%)   7 (15.9%)   18 (14.4%) 0.349
History of CAD  14 (10.7%)*  1 (2.3%)†    1 (0.8%)† 0.001
History of CVA  1 (0.8%)*  3 (6.8%)†    15 (12.0%)† 0.001
Creatinine (mg/dL)   1.1 ± 0.6   0.9 ± 0.3   0.9 ± 0.3 0.052
Total cholesterol (mg/dL) 165.6 ± 47.8 177.0 ± 54.1 168.4 ± 55.9 0.467
LDL cholesterol (mg/dL) 100.7 ± 43.3   96.8 ± 51.0 103.9 ± 34.1 0.944
HDL cholesterol (mg/dL)   42.5 ± 13.3   42.4 ± 16.8   40.7 ± 12.5 0.624
Triglyceride (mg/dL) 126.3 ± 66.9 148.3 ± 81.9   145.2 ± 106.1 0.110
CRP (mg/L)   12.4 ± 36.5   9.3 ± 8.8   14.2 ± 19.2 0.899
BNP (pg/mL)   261.6 ± 317.7   298.5 ± 506.6   202.2 ± 282.6 0.659
D-dimer (µg/mL)     33.9 ± 161.4   11.3 ± 14.7   12.4 ± 10.2 0.197
Shock on admission 9 (6.9%) 4 (9.1%) 11 (8.8%) 0.313
Surgery or thrombolytics 9 (6.9%) 4 (9.1%) 11 (8.8%) 0.313
Statistical significance was evaluated by ANOVA and chi-squared test. *,†The same letters indicate insignificant differences between groups based on Tukey’s multiple compari-
son test. rRF, reversible risk factor; iRF, irreversible risk factor; BMI, body mass index; CAD, coronary artery disease; CVA, cerebrovascular accident; LDL, low-density lipoprotein; 
HDL, high-density lipoprotein; CRP, C-reactive protein; BNP, B-type natriuretic peptide. 
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Imaging parameters 
The numbers of patients who underwent both CT and echocar-
diography were 87, 27, and 80 in the unprovoked, provoked-rRF, 
and provoked-iRF groups, respectively. There were no signifi-
cant differences in imaging parameters between the 3 groups 
(Table 3). 
Table 2. Risk factors for pulmonary embolism in the provoked group
Risk factors Frequency (%)
Cancer 
   Lung
   Biliary tract 
   Colon 
   Hematologic 
   Stomach
   Liver 
   Pancreas
   Gynecologic
   Breast
   Urologic 
   Brain 
   Oronasopharyngeal 
   Miscellaneous
111 (65.7) 
37 (33.3)
9 (8.1)
9 (8.1)
9 (8.1)
7 (6.3) 
7 (6.3) 
6 (5.4) 
6 (5.4) 
5 (4.5) 
4 (3.6) 
3 (2.7) 
2 (1.8)
7 (6.3)
Immobilization 
   Neurologic sequelae
   Fracture of the lower extremities
   Admission to ICU due to medical disease
   Major surgery
57 (33.7)
22 (38.6)
14 (24.6)
12 (21.1)
9 (15.8)
Estrogen supplementation 1 (0.6) 
Table 3. Computed tomography and echocardiographic data
Image items
Unprovoked 
(n = 87)
Provoked-rRF 
(n = 27)
Provoked-iRF 
(n = 80)
P  value
CT RVD (mm) 42.1 ± 8.7 42.2 ± 7.9 41.4 ± 9.1 0.706
CT LVD (mm) 40.1 ± 7.9 38.9 ± 7.5 38.3 ± 7.2 0.135
CT RV/LV ratio   1.1 ± 0.4   1.1 ± 0.4   1.1 ± 0.4 0.980
CT PA (mm) 31.0 ± 5.0 31.6 ± 6.0 31.0 ± 4.8 0.833
CT Ao (mm) 36.2 ± 5.0 35.2 ± 4.1 35.4 ± 4.7 0.224
CT PA/Ao ratio   0.9 ± 0.2   0.9 ± 0.1   0.9 ± 0.1 0.358
CT obstruction index (%) 14.2 ± 7.5 15.0 ± 7.5 12.5 ± 6.8 0.290
RVEDD (mmHg) 30.6 ± 9.6 29.8 ± 16.6 27.0 ± 9.9 0.347
TR grade
   No
   Mild
   Moderate
   Severe
 
17.9%
44.9%
24.4%
12.8%
 
21.1%
47.4%
31.6%
     0%
 
20.9%
55.8%
16.3%
  7.0%
0.499
SPAP (mmHg)   53.4± 25.8   51.2± 17.8   49.4± 16.2 0.122
LVEF (%) 63.3 ± 8.6   58.6± 17.0 64.2 ± 7.8 0.559
Statistical significance was evaluated by ANOVA and  chi-squared test. rRF, reversible 
risk factor; iRF, irreversible risk factor; CT, computed tomography; RV, right ventricle; 
LV, left ventricle; CT RVD, RV dimension from CT; CT LVD, LV dimension from CT; PA, 
pulmonary artery; Ao, aorta; CT PA, pulmonary artery diameter from CT; CT Ao, aorta 
diameter from CT; RVEDD, RV end-diastolic dimension from echocardiography; TR, 
tricuspid regurgitation; SPAP, systolic pulmonary artery pressure; LVEF, LV ejection 
fraction.
Fig. 2. Cumulative mortality and recurrence rate in each group. (A) Cumulative all-
cause mortality, (B) cumulative mortality from pulmonary embolism (PE), and (C) cu-
mulative recurrence of PE by Kaplan-Meier method between unprovoked, provoked 
with reversible risk factors (provoked-rRF), and provoked with irreversible risk factors 
(provoked-iRF) groups.
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Treatment
The numbers of patients treated with surgery or thrombolytics 
were 10 (3.3%) and 16 (5.3%), respectively. The numbers of pa-
tients treated with unfractionated heparin only or low molecu-
lar weight heparin only were 77 (25.7%), and 197 (65.7%), re-
spectively. After discharge, warfarin was maintained for all sur-
vivors who had no contraindications of anticoagulation for 3 to 
6 months. The proportions of patients with time in therapeutic 
range of anticoagulation > 60% were 68.7%, 73.5%, and 67.6% 
in the unprovoked, provoked-rRF, and provoked-iRF groups, 
respectively. There were no significant differences in time in 
therapeutic range of anticoagulation between the groups (P =  
0.455). Inferior vena cava filtering was performed for 37 (12.3%) 
patients; 16 (12.2%), 10 (22.7%), and 11 (8.8%) in the unprovoked, 
provoked-rRF, and provoked-iRF groups, respectively. There 
were no significant differences in the numbers of patients who 
underwent inferior vena cava filtering between the groups (P =  
0.054). 
Mortality 
The all-cause mortality and mortality from PE during the follow-
up period was 33.3%, and 18.7%, respectively. The all-cause 
mortality in the unprovoked, provoked-rRF, and provoked-iRF 
groups were 15.3%, 18.2%, and 56.8%, respectively. Mortality 
from PE in the unprovoked, provoked-rRF, and provoked-iRF 
groups were 9.2%, 11.4%, and 31.2%, respectively. By the Kaplan-
Meier method, the provoked-iRF group had significantly higher 
all-cause mortality, mortality from PE and recurrence of PE than 
the unprovoked and provoked-rRF groups (P < 0.001, P < 0.001 
and P = 0.034, respectively; Fig. 2). However, there were no sig-
nificant differences of all-cause mortality, mortality from PE, 
and recurrence of PE between the unprovoked and provoked-
rRF groups (P = 0.377, P = 0.495, and P = 0.410, respectively). 
Clinical factors related to the composite endpoint 
The rate of composite endpoint was 36.6% in all patients and 
19.8%, 20.5%, and 60.0% in the unprovoked, provoked-rRF, and 
provoked-iRF groups, respectively. By univariate analysis, cre-
atinine, CRP, and shock on admission were significantly related 
to the composite endpoint in the unprovoked group. Age, BMI, 
HDL cholesterol, cancer, and metastatic cancer were significant-
ly related to composite endpoint in the provoked-iRF group. 
Age, BMI, total cholesterol, HDL cholesterol, and D-dimer were 
significantly related to the composite endpoint in the provoked-
rRF group. By multivariate analysis, prognostic factors signifi-
cantly related to composite endpoint in the unprovoked group 
were creatinine (> 1.2 mg/dL; P < 0.001), and CRP (> 5 mg/L; 
P = 0.002). In the provoked-iRF group, the prognostic factors 
significantly related to the composite endpoint was metastatic 
cancer (P = 0.011; Table 4). There were no significant prognostic 
factors for the composite endpoint in the provoked-rRF group. 
Imaging parameters related to the composite endpoint 
By univariate analysis, CT RV/LV ratio, and CT obstruction in-
dex were significantly related to the composite endpoint in the 
unprovoked group; no imaging parameters were significant in 
the provoked groups. By multivariate analysis, the CT obstruc-
tion index was significantly related to the composite endpoint 
in the unprovoked group (P = 0.034; Table 4). 
DISCUSSION
This was a retrospective study to elucidate the clinical and im-
aging characteristics, mortality, and prognostic factors in pa-
tients with unprovoked PE, provoked PE with reversible risk fac-
tors, and provoked PE with irreversible risk factors. This study 
showed that the unprovoked group was related to smoking and 
history of CAD, and that provoked-iRF group had higher mor-
Table 4. Clinical and imaging parameters related to the composite endpoint on multivariate analysis
Parameters 
Unprovoked Provoked-rRF Provoked-iRF
 P  value HR (95% CI) P  value HR (95% CI) P  value HR (95% CI)
Age > 65 yr - - 0.713    29.328 (0.0-1870000000) 0.186   2.662 (0.625-11.339)
BMI > 25 kg/m2 - - 0.381      0.001 (0.0-7023.358) 0.978 0.981 (0.254-3.789)
Creatinine > 1.2 mg/dL < 0.001   4.735 (1.845-12.152) - - - -
Total cholesterol > 200 mg/dL - - 0.965      0.669 (0.0-48775165) - -
HDL cholesterol < 40 mg/dL - - 0.687    42.198 (0.0-3330000000) 0.084   3.554 (0.842-14.994)
CRP > 5 mg/L     0.002   5.308 (1.824-15.447) - - - -
D-dimer > 20 µg/mL - - 0.662 120.719 (0.0-269000000000) - -
Shock on admission     0.974 0.975 (0.209-4.556) - - - -
Cancer - - - - 0.459 0.423 (0.043-4.131)
Metastatic cancer - - - - 0.011   19.324 (1.990-187.653)
CT RV/LV ratio     0.146 2.371 (0.740-7.595) - - - -
CT obstruction index     0.034 1.090 (1.006-1.181) - - - -
Statistical significance was evaluated by Cox proportional hazard model. -, P  value > 0.1 on univariate analysis. rRF, reversible risk factor; iRF, irreversible risk factor; HR, haz-
ard ratio; CI, confidence interval; BMI, body mass index; HDL, high-density lipoprotein; CRP, C-reactive protein; CT, computed tomography; RV, right ventricle; LV, left ventricle; 
CT RV/LV ratio, RV dimension/LV dimension from CT.
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tality than the unprovoked and provoked-rRF groups. In addi-
tion, this study showed that creatinine, CRP, and CT obstruction 
index were poor prognostic factors in unprovoked PE. 
 It is not surprising that CVA is more frequent in the provoked 
group because patients with neurologic sequelae due to CVA 
were included in the provoked groups. Recent studies showed 
strong associations between unprovoked PE and risk factors of 
atherosclerosis (6, 7, 9). The associations of unprovoked PE with 
smoking or CAD reported here are consistent with previous 
studies. However, the lack of associations with other risk factors 
including age, sex, BMI, hypertension, diabetes, and hyperlipid-
emia are not consistent. This may be explained by the fact that 
although PE and atherosclerosis share the common pathophys-
iology of endothelial dysfunction and abnormal blood compo-
nents, blood stasis in veins could be different from that in arter-
ies (4, 16).
 Recent studies reported that shock on admission, high levels 
of BNP or troponin, RV dilation on CT or echocardiography, RV 
dysfunction, massive PE and CT obstruction index were signifi-
cant predictors of mortality (11, 17-21). In this study, however, 
only the CT obstruction index was a significant prognostic fac-
tor in unprovoked PE; other factors including shock on admis-
sion, high BNP, and RV dilation were not significant prognostic 
factors. This might be due to the influence of hemodynamic in-
stability on short-term mortality, but not long-term mortality 
and recurrence of PE. CT obstruction index was correlated with 
the amount of embolism. Our data indicate that a large amount 
of embolism is related to poor prognosis. 
 In this study, renal insufficiency and a marker of the inflam-
matory response were also found to be important prognostic 
factors in unprovoked PE, in addition to the amount of throm-
bus in the pulmonary arteries. It has been reported that chronic 
kidney disease is associated with increased risk of venous throm-
boembolism (22). In this study, poor prognosis in patients with 
renal insufficiency might be related to risk of venous thrombo-
embolism. 
 It has been reported that high CRP is related to risk of venous 
thromboembolism (23, 24). However, the mechanisms of asso-
ciation of CRP with risk of venous thromboembolism are not 
clear (25, 26). However, elevated CRP has not been previously 
reported to be related to PE prognosis. We suggest that CRP is 
important in predicting prognosis of unprovoked PE. In the 
provoked-iRF groups, there were no prognostic factors except 
metastatic cancer; this is likely because the underlying disease, 
general physical condition, or deconditioning of the patients 
may be more influential than PE itself on prognosis. It is known 
that unprovoked PE has high recurrence rate. The reason of no 
significant differences of recurrence rate between unprovoked 
and provoked PE with reversible cause in the present study could 
be because many patients with unprovoked PE were treated 
with long-term anticoagulation therapy. 
 There were no studies that evaluated clinical characteristics 
and mid- to long-term prognosis of PE classified into unpro-
voked, provoked-rRF, and provoked-iRF. We demonstrated that 
provoked PE with irreversible risk factors has higher all-cause 
mortality, mortality from PE and recurrence of PE than both un-
provoked PE and provoked PE with reversible risk factors. This 
is likely due to the fact that patients with provoked PE and irre-
versible risk factors had more serious comorbidities including 
refractory cancer, and neurologic sequelae. It is not surprising 
that patients in the provoked-iRF group had a higher recurrence 
rate than the unprovoked and provoked-rRF groups because 
they had risk factors for a life-long period after the first episode 
of PE. 
 Because we did not perform CT and echocardiography in ev-
ery patient, we did not analyze CT and echocardiographic data 
from the entire study population. Severity of RV dysfunction was 
not analyzed in this study because quantification methods of 
RV dysfunction were not consistent for the study period. Cardi-
ac markers such as creatine kinase-MB and troponin were not 
included, because these cardiac markers were not checked rou-
tinely in patients with PE at our center. Markers related to inher-
ited thrombophilia such as protein C, protein S, and coagula-
tion factors are also not included into this study because blood 
was sampled after heparin injection in some patients. 
 In conclusion, provoked PE with irreversible risk factors has 
a poorer prognosis than unprovoked PE and provoked PE with 
reversible risk factors. Prognosis of unprovoked PE is not differ-
ent from that of provoked PE with reversible risk factors. Unpro-
voked PE is related to risk factors for atherosclerosis, including 
smoking, and history of CAD. Renal insufficiency, high CRP, 
and CT obstruction index are significant prognostic factors of 
unprovoked PE. We suggest that patients with unprovoked PE 
combined with renal insufficiency, elevated CRP, or a high CT 
obstruction index should be monitored more closely for poten-
tial adverse outcomes and that aggressive anticoagulation should 
be performed for patients with provoked PE with irreversible 
risk factors.
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